Cover Image
市場調查報告書

抗肥胖藥的美國市場:2015-2019年

Anti-obesity Drugs Market in the US 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 336069
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
抗肥胖藥的美國市場:2015-2019年 Anti-obesity Drugs Market in the US 2015-2019
出版日期: 2015年07月22日 內容資訊: 英文 82 Pages
簡介

美國的抗肥胖藥市場預計從2014年到2019年以24.52%的年複合成長率成長。

本報告提供美國的抗肥胖藥的市場相關調查、肥胖症概要、主要的產品簡介、市場規模的變化與預測、抗肥胖藥的藥物類別與投藥類型、市場成長的各種影響因素分析、競爭環境與市場佔有率,以及主要企業的簡介等彙整。

第1章 摘要整理

第2章 簡稱集

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介

  • Xenical
  • Qsymia
  • Belviq
  • Saxenda
  • Contrave

第5章 市場調查手法

第6章 簡介

第7章 疾病概要

  • 關於疾病
  • 病因、共生病症
  • 肥胖症的分類
  • 流行病學
  • 肥胖症的經濟負擔

第8章 市場環境

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第9章 抗肥胖藥的藥物類別

  • 末梢作用性抗肥胖藥
  • 中樞作用性抗肥胖藥

第10章 抗肥胖藥的投藥類型

  • 單劑療法
  • 多劑聯合治療

第11章 購買標準

第12章 市場促進因素

第13章 成長推進因素與其影響

第14章 市場上課題

第15章 成長推進因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 供應商環境

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Vivus
    • Arena Pharmaceuticals
    • Orexigen Therapeutics
    • Novo Nordisk
  • 其他的有力供應商

第19章 主要供應商分析

  • Arena Pharmaceuticals
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Orexigen Therapeutics
  • Vivus
  • Novo Nordisk
    • 主要資料
    • 產業概要
    • 各產業收益
    • 各地區收益
    • 產業策略
    • 近幾年的發展趨勢
    • SWOT分析等

第20章 相關報告

圖表

目錄
Product Code: IRTNTR6729

About Obesity

Obesity is a complex multifactorial disorder characterized by the excessive accumulation and storage of fat in the body. In the recent years, this chronic illness is being considered as a global epidemic owing to its strikingly increasing incidence rates, especially in the in low and middle-income countries. Sedentary lifestyles and lack of physical activity coupled with consumption of high-calorie diet are considered to be the most preventable causes of obesity. Being either overweight or obese is considered as a risk factor for the development of multiple chronic diseases including cardiovascular disorders such as coronary heart disease, dyslipidemia, hypertension; metabolic disorders such as diabetes; and cancers to highlight a few. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.

Technavio's analysts forecast the anti-obesity drugs market in the US to grow at a CAGR of 24.52% over the period 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the anti-obesity drugs market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the currently approved patented drugs, generics, OTC products, and the available generics that are used for the treatment of obesity.

Technavio's report, Anti-obesity Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the

key vendors operating in this market.

Key Vendors

  • Arena Pharmaceuticals
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novo Nordisk
  • Orexigen Therapeutics
  • Vivus

Other Prominent Vendors

  • Alizyme
  • Amylin
  • Boehringer Ingelheim
  • Eisai
  • Merck
  • Norgine
  • Pfizer
  • Rhythm Pharmaceuticals
  • Shionogi USA
  • Takeda Pharmaceutical
  • Zafgan

Key Market Driver

  • Growing Prevalence Population
  • For a full, detailed list, view our report

Key Market Challenge

  • Serious Adverse Events and Multiple Drug Withdrawals
  • For a full, detailed list, view our report

Key Market Trend

  • Diversification of Investigational Pipeline
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

  • 04.1. Xenical
  • 04.2. Qsymia
  • 04.3. Belviq
  • 04.4. Saxenda
  • 04.5. Contrave

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

    • 07.1.1. Understanding the Disease
    • 07.1.2. Etiology and Comorbidities
    • 07.1.3. Classification of Obesity
    • 07.1.4. Epidemiology
    • 07.1.5. Economic Burden Due to Obesity

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Drug Class

  • 09.1. Peripherally Acting Anti-obesity Drugs
  • 09.2. Centrally Acting Anti-obesity Drugs

10. Market Segmentation by Medication Type

  • 10.1. Monotherapies
  • 10.2. Polytherapies

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and Their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and Their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. F. Hoffmann-La Roche
    • 18.2.2. GlaxoSmithKline
    • 18.2.3. Vivus
    • 18.2.4. Arena Pharmaceuticals
    • 18.2.5. Orexigen Therapeutics
    • 18.2.6. Novo Nordisk
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Arena Pharmaceuticals
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Geographical Segmentation
    • 19.1.4. Business Strategy
    • 19.1.5. Recent Developments
    • 19.1.6. SWOT Analysis
  • 19.2. F. Hoffmann-La Roche
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation
    • 19.2.4. Business Segmentation by Revenue 2012 and 2013
    • 19.2.5. Geographical Segmentation by Revenue
    • 19.2.6. Business Strategy
    • 19.2.7. Key Information
    • 19.2.8. SWOT Analysis
  • 19.3. GlaxoSmithKline
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation
    • 19.3.4. Business Segmentation by Revenue 2012 and 2013
    • 19.3.5. Sales by Geography
    • 19.3.6. Pipeline Products
    • 19.3.7. Business Strategy
    • 19.3.8. Key Information
    • 19.3.9. SWOT Analysis
  • 19.4. Orexigen Therapeutics
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Strategy
    • 19.4.4. Recent Developments
    • 19.4.5. SWOT Analysis
  • 19.5. Vivus
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation by Revenue 2013
    • 19.5.4. Business Segmentation by Revenue 2012 and 2013
    • 19.5.5. Geographical Segmentation by Revenue 2013
    • 19.5.6. Business Strategy
    • 19.5.7. Recent Information
    • 19.5.8. SWOT Analysis
  • 19.6. Novo Nordisk
    • 19.6.1. Key Facts
    • 19.6.2. Business Overview
    • 19.6.3. Business Segmentation by Revenue 2013
    • 19.6.4. Business Segmentation by Revenue 2012 and 2013
    • 19.6.5. Sales by Geography
    • 19.6.6. Business Strategy
    • 19.6.7. Key Information
    • 19.6.8. SWOT Analysis

20. Other Reports in This Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Causes and Comorbidities of Obesity
  • Exhibit 3: Prevalence of Adults Overweight or Obese in US
  • Exhibit 4: Prevalence of Adults Overweight or Obese in US
  • Exhibit 5: Prevalence Rate of Children Overweight or Obese in US
  • Exhibit 6: Anti-obesity Drugs Market in US 2014-2019 ($ millions)
  • Exhibit 7: Segmentation of Anti-obesity Drugs Market in US by Drug Class
  • Exhibit 8: Segmentation of Anti-obesity Drugs Market in US by Medication Type
  • Exhibit 9: Pipeline Snapshot
  • Exhibit 10: Key Takeaways: F. Hoffman-La Roche
  • Exhibit 11: Key Takeaways: GlaxoSmithKline
  • Exhibit 12: Key Takeaways: Vivus
  • Exhibit 13: Key Takeaways: Arena Pharmaceuticals
  • Exhibit 14: Key Takeaways: Orexigen
  • Exhibit 15: Key Takeaways: Novo Nordisk
  • Exhibit 16: Arena Pharmaceuticals: Geographical Segmentation
  • Exhibit 17: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 18: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 19: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
  • Exhibit 20: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
  • Exhibit 21: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 22: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 ($ billions)
  • Exhibit 23: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 24: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 25: Vivus: Business Segmentation by Revenue 2013
  • Exhibit 26: Vivus: Business Segmentation by Revenue 2012 and 2013 ($ millions)
  • Exhibit 27: Vivus: Geographical Segmentation by Revenue 2013
  • Exhibit 28: Novo Nordisk: Business Segmentation by Revenue 2013
  • Exhibit 29: Novo Nordisk: Business Segmentation by Revenue 2012 and 2013 ($ billions)
  • Exhibit 30: Novo Nordisk: Sales by Geography 2013
Back to Top